Chylomicron APOB48 is increased in diabetic patients

被引：0
|
作者：
Matsushima, T.
Fujita, R.
Kinoshita, K.
Teramoto, T.
机构：
[1] Tsukuba Mem Hosp, Tsukuba, Ibaraki, Japan
[2] Teikyo Univ, Tokyo 173, Japan
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2006年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1567-5688(06)82043-X
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：510 / 511
页数：2
相关论文
共 50 条
  • [1] Could the chylomicron marker apoB48 be of value in the diagnosis of chylous effusions?
    Lefrere, Bertrand
    Sakka, Mehdi
    Fourati, Salma
    Levasseur, Antoine
    Curis, Emmanuel
    Cherfils, Corinne
    Gres, Pierre
    Guilbert, Zoe
    Lacorte, Jean-Marc
    Cheneviere, Cristina
    Bittar, Randa
    Bonnefont-Rousselot, Dominique
    CLINICA CHIMICA ACTA, 2023, 539 : 184 - 190
  • [2] Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome
    Mangat, R.
    Su, J.
    Scott, P. G.
    Russell, J. C.
    Vine, D. F.
    Proctor, S. D.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 : 477 - 481
  • [3] Liraglutide reduces postprandial hyperlipidaemia by increasing apoB48 catabolism and by reducing apoB48 production
    Verges, B.
    Duvillard, L.
    Bouillet, B.
    Baillot-Rudoni, S.
    Buffier, P.
    Crevisy, E.
    Peut, J. -M.
    DIABETOLOGIA, 2016, 59 : S310 - S311
  • [4] Analysis of chylomicron apoB48 secretion using everted intestinal sac system; effects of food ingredients
    Tomishige, K.
    Matsushima, T.
    FEBS JOURNAL, 2017, 284 : 353 - 353
  • [5] Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
    Verges, Bruno
    Duvillard, Laurence
    de Barros, Jean Paul Pais
    Bouillet, Benjamin
    Baillot-Rudoni, Sabine
    Rouland, Alexia
    Sberna, Anne-Laure
    Petit, Jean-Michel
    Degrace, Pascal
    Demizieux, Laurent
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (09) : 2198 - 2206
  • [6] Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics
    Bjornson, E.
    Packard, C. J.
    Adiels, M.
    Andersson, L.
    Matikainen, N.
    Soderlund, S.
    Kahri, J.
    Sihlbom, C.
    Thorsell, A.
    Zhou, H.
    Taskinen, M. -R.
    Boren, J.
    JOURNAL OF INTERNAL MEDICINE, 2019, 285 (05) : 562 - 577
  • [7] A mouse monoclonal antibody specific for mouse apoB48 and apoB100 produced by immunizing "apoB39-only" mice with mouse apoB48
    Nguyen, AT
    Braschi, S
    Geoffrion, M
    Fong, LG
    Crooke, RM
    Graham, MJ
    Young, SG
    Milne, R
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2006, 1761 (02): : 182 - 185
  • [8] Postprandial ApoB48 Levels Determined Using ELISA in Diabetic and Normal Subjects.
    Leonard, A.
    Tun, T. Kyaw
    Gaffney, P.
    Sharma, J.
    Gibney, J.
    Boran, G.
    ENDOCRINE REVIEWS, 2010, 31 (03) : S33 - S33
  • [9] ApoB48 as an Efficient Regulator of Intestinal Lipid Transport
    Lo, Chunmin C.
    Coschigano, Karen T.
    FRONTIERS IN PHYSIOLOGY, 2020, 11
  • [10] Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice
    Alipour, Arash
    Valdivielso, Pedro
    Elte, Jan Willem F.
    Janssen, Hans W.
    Rioja, Jose
    van der Meulen, Noelle
    van Mechelen, Rob
    Njo, Tjin L.
    Gonzalez-Santos, Pedro
    Rietveld, Arie P.
    Cabezas, Manuel Castro
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (07) : 702 - 708
12345